Key Highlights

  • Price $390.38 (+2.9% today) · Market cap $134.4 billion · BMO Capital sets $518 price target on Intuitive Surgical · Next catalyst: da Vinci 5 upgrade cycle in early stages
  • Intuitive Surgical reported Q1 EPS of $2.50, topping the $2.14 consensus estimate
  • Shares down 30.5% year-to-date but rose 2.9% after BMO’s Outperform rating
  • Analyst Vik Chopra cited durable earnings and expansion into new specialties as key drivers

Intuitive Surgical delivered a stronger-than-expected quarter, reporting earnings per share of $2.50 that surpassed the $2.14 consensus estimate. The beat comes as BMO Capital initiated coverage with an Outperform rating and a $518 price target, sending shares up 2.9% in recent trading.

Earnings Beat Fuels Optimism

Intuitive Surgical’s first-quarter results exceeded analyst expectations, with EPS of $2.50 compared to the $2.14 estimate. The company, which develops minimally invasive surgical systems, has seen its shares decline 30.5% year-to-date, but the earnings beat provided a near-term lift. BMO Capital analyst Vik Chopra highlighted the durability of Intuitive’s earnings stream, noting that procedure growth is expanding into additional specialties and markets.

This suggests the company’s core business remains resilient despite broader market pressures.

BMO’s Bullish Call Contrasts With Peers

BMO Capital set a $518 price target on Intuitive Surgical, the highest among recent analyst adjustments. Evercore ISI lowered its target to $430 from $480 just days earlier, maintaining an In Line rating, while Bank of America trimmed its target to $515 from $520 but kept a Buy rating. Chopra’s Outperform rating stands out as the most optimistic, driven by the early stages of the da Vinci 5 upgrade cycle.

The divergence in targets reflects mixed sentiment on how quickly the new system will drive adoption and revenue growth.

Shares Rebound After Steep Decline

Intuitive Surgical’s stock, which has fallen 30.5% this year and 5% over the past month, rose 2.9% to $390.38 following BMO’s upgrade. The company’s market capitalization now stands at $134.4 billion, with shares trading well below their 52-week high of $603.88. The recent rally suggests investors are responding to signs of stabilization, though the stock remains under pressure from broader market volatility and sector rotation.

The durability of Intuitive’s earnings, as noted by Chopra, could be a key factor in sustaining momentum.

Upgrade Cycle and Growth Prospects

The da Vinci 5 system’s early adoption phase is central to BMO’s bullish thesis. Chopra highlighted the prospect of higher procedure volumes over time as a long‑term catalyst. While competitors are entering the surgical robotics space, Intuitive’s established installed base and recurring revenue from instruments and accessories provide a buffer.

The next major catalyst will be the pace of da Vinci 5 installations, which could determine whether the stock regains its upward trajectory or faces further headwinds.

Based on BMO Capital’s initiation report released 9 July 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.